

# Christian Uprimny

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281410/publications.pdf>

Version: 2024-02-01

31  
papers

1,335  
citations

567281

15  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1940  
citing authors

#	ARTICLE	IF	CITATIONS
1	68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 941-949.	6.4	247
2	68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1284-1294.	6.4	234
3	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	6.4	152
4	Current status of theranostics in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 471-495.	6.4	115
5	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	6.4	91
6	Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1585-1592.	6.4	74
7	Early dynamic imaging in 68Ga-PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 765-775.	6.4	69
8	Early PET imaging with [68Ga]-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1647-1655.	6.4	41
9	Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1873-1883.	6.4	41
10	The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 695-712.	6.4	37
11	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	12.8	34
12	68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 362-363.	6.4	31
13	Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2072-2083.	6.4	31
14	Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survival. <i>World Journal of Urology</i> , 2020, 38, 417-424.	2.2	25
15	Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 935-936.	6.4	18
16	68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 3-11.	1.1	14
17	Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 123-133.	6.4	13
18	Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for <sup>68</sup> Ga-PSMA-11 PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1550-1557.	5.0	13

#	ARTICLE	IF	CITATIONS
19	Bi-insular cortical involvement in anti-NMDA-receptor encephalitis – a case report. BMC Neurology, 2016, 16, 130.	1.8	12
20	Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: Case report and review of the literature. Journal of Clinical Virology, 2014, 60, 424-427.	3.1	10
21	Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals, 2021, 14, 575.	3.8	7
22	Cardiac sympathetic innervation in Parkinson’s disease versus multiple system atrophy. Clinical Autonomic Research, 2022, 32, 103-114.	2.5	7
23	Thyroid carcinoma detected by incidental 18F-FDG uptake in a patient with progressive cerebellar syndrome. Endocrine, 2016, 51, 199-200.	2.3	5
24	Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. Life, 2021, 11, 198.	2.4	4
25	Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. Diagnostics, 2021, 11, 1191.	2.6	4
26	Influence of the anterior notch in mobile-bearing UKA on patellofemoral radiotracer uptake and clinical outcome. BMC Musculoskeletal Disorders, 2017, 18, 532.	1.9	2
27	Disseminated focal 18F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia. Therapeutic Advances in Hematology, 2020, 11, 204062072097761.	2.5	2
28	PET in lymphoma: who, when, how often, pitfalls?. Memo - Magazine of European Medical Oncology, 2015, 8, 43-47.	0.5	1
29	When cardiac surgery comes to its limits: a case report of pericardial mesothelioma invading the myocardium. European Heart Journal - Case Reports, 2021, 5, ytab237.	0.6	1
30	Visualization of malignant infiltration of the thoracic duct on 68Ga PSMA-11 PET/CT in a prostate cancer patient with biochemical recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2042-2043.	6.4	0
31	Fast Achievement Of a First Metabolic Complete Remission In a Lung Transplanted Patient With Multiple Comorbidities and CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy. Blood, 2013, 122, 5124-5124.	1.4	0